Navigation Links
First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System
Date:5/22/2013

he system; 97.6 percent of the patients had a PVL <= mild, severe PVL did not occur (0.0 percent).

The data was presented by Stephan Ensminger , MD, PhD, from the Heart and Diabetes Center NRW in Bad Oeynhausen, Germany, on behalf of the registry investigators. "The JUPITER registry confirms the excellent performance and safety of this 2nd generation TAVI system in a real world clinical use," said Dr. Ensminger.

"The very good stroke and PVL data is especially impressive. With no PVL > mild and only 2.3 percent of moderate PVL, the JenaValve TAVI system shows one of the lowest PVL rates reported in a TAVI registry," added Helmut J. Straubinger , CEO of JenaValve Technology.

About TAVI

Transcatheter aortic valve implantation systems (TAVI) have already yielded nearly $1 billion in revenues worldwide and the market is expected to grow to over $3 billion in 20161. Clinicians are now focused increasingly on TAVI technical and procedural refinements and advancements found in second-generation products such as JenaValve's which address and resolve issues including ease of implantation, the need for post-procedure pacemaker implantation and post-implant paravalvular leakage.

About the JenaValve™ TAVI System

The JenaValve is a true second-generation catheter-based aortic valve implantation system engineered and manufactured to the highest quality standards. The JenaValve transapical TAVI system is currently being sold in Europe. The Company's transfemoral TAVI system is expected to enter into clinical study later in 2013 and is anticipated to be available for sale in 2014.

  • The JenaValve prosthesis consists of a natural aortic porcine root bioprosthesis fitted with an outer porcine pericardial patch, a so-called skirt, before being sew
    '/>"/>

SOURCE JenaValve Technology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Thoratec Schedules First Quarter Conference Call, Webcast
3. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
4. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
7. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
8. Insmed to Host 2012 First Quarter Earnings Conference Call
9. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
10. Henry Schein to Webcast First Quarter 2012 Conference Call Tuesday, May 8, at 10:00 a.m. EDT
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ROSEMONT, Ill. , Aug. 3, 2015 ... ankle problem, and you,re looking for the best possible ... for the best outcome too, and now there,s a ... there. Following steps recommended by the American Orthopaedic ... after surgery can help you avoid complications and heal ...
(Date:8/3/2015)... FRANCISCO , Aug. 3, 2015  Sage Analytics ... of portable laboratory-quality cannabis potency measurement systems, announced its ... Bay Area Cruise Fundraiser. A limited number of tickets ... festivities and help a great cause while enjoying an ... scenic cruise around the San Francisco Bay at sunset. ...
(Date:8/3/2015)... FRANCISCO , August 3, 2015 ... size is expected to reach USD 24.7 billion ... Grand View Research Inc. Growing prevalence of neurological ... physiotherapy equipments market over the forecast period. The ... ultrasound and cryotherapy, advancement in the technologies coupled ...
Breaking Medicine Technology:Patient Guide: How to Prepare for Surgery 2Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5
... Echo Therapeutics, Inc. (OTC Bulletin Board: ... System as a non-invasive, wireless, transdermal continuous glucose monitoring ... delivery, today announced that it has raised approximately $2.5 ... Company,s stock and warrants, and it has received a ...
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... officer, is scheduled to present a company overview at the ... January 13th at 11:30 a.m. PST. (Logo:   ... or the subsequent archived recording, log on to www.rigel.com ...
Cached Medicine Technology:Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million 2Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million 3Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million 4
(Date:8/3/2015)... Ore. (PRWEB) , ... August 03, 2015 , ... They ... Providence St. Vincent Medical Center offers some of the best care in ... M.D., neurosurgeon and neurointerventionalist, achieved the fastest average blood clot removal time in the ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of Appeals ruled in favor of the firm’s client Rebecca Hamsher, deciding that ... Medical Center must reimburse benefits for Hamsher’s residential treatment for bulimia, depression and ...
(Date:8/3/2015)... PA (PRWEB) , ... August 03, 2015 , ... ... Africa , Infectious diseases researchers from the University of Pittsburgh School of Medicine ... rollout of HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can ... costs. , Annually, more than 8.6 million adverse drug events are reported ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the ... and consumer health products, today welcomed the announcement by OPKO Health that the ... for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... Inc.,(Nasdaq: ATRC ), a medical device company ... announced that its minimally invasive platform was,highlighted during ... techniques. On June 18, Dr. Kenneth,Ellenbogen, Vice Chairman ... Pacing at the Medical College of Virginia, chaired ...
... on MRIs with limited side effects, study found , , FRIDAY, ... to treat the "relapse-remitting" form of multiple sclerosis has been ... , Although the drug, laquinimod, is still experimental, having a ... patients. , "By and large, this doesn,t look as strong ...
... PRGO ; TASE) today announced that it ... Drug Administration to manufacture and market,Cetirizine Hydrochloride Syrup ... Consumer Healthcare,s Zyrtec(R) Syrup, 1mg/mL, indicated for the,relief ... Perrigo,s Chairman and CEO Joseph C. Papa stated, ...
... no added benefit , , THURSDAY, June 19 (HealthDay News) ... risk of HIV-1 infection in people who have sex ... finds. , Previous research has shown that herpes simplex ... of genital herpes -- increases the risk for HIV-1 ...
... Bills Delay and Fix Competitive Bidding System for ... Pete Stark,(D-CA), chair of the House Ways & ... DMEPOS Competitive Acquisition Reform,Act of 2008. Sens. Max ... member of the Senate Finance Committee, have introduced ...
... The results of a major international clinical trial coordinated ... the New England Journal of Medicine . The ... a prospective, multicentre project involving patients with heart failure ... of death in the population and associated atrial fibrillation ...
Cached Medicine News:Health News:The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France 2Health News:The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France 3Health News:The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France 4Health News:Experimental Drug Fights Multiple Sclerosis Activity 2Health News:Experimental Drug Fights Multiple Sclerosis Activity 3Health News:Perrigo Announces Approval for Rx Cetirizine Syrup 2Health News:Herpes Suppression May Not Prevent HIV Infection 2Health News:NCPA Statement Endorsing H.R. 6252 and S.3144 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 3
Swedish Knee Cage -- hinged to track knee motion. Effective control of genu recurvatum (back knee or knee hyperextension). Fits left or right....
... The Infrapatellar Band uses an ... the patellar tendon helping to ... and patella tendonitis. Focusing the ... tibial tubercle with less constriction ...
Designed to provide continuous cold therapy to the shoulder and back. Helps to reduce pain and swelling and speed rehab....
... immobilization following shoulder fusion, dislocation, reconstruction ... allows the shoulder to be positioned ... Following brachial plexus injury this orthosis ... stretch during the healing process and ...
Medicine Products: